Popular on Amzeal
- Terrorist? Thats What This Entrepreneur Grew Up Being Called, That Didn't Stop Him
- NRAO Program Looking for Students 18-20 Years Old to Learn About the Electromagnetic Spectrum
- Laboratory Supply Distributors Corp. Launches New Chromatography Consumables Website and Brand
- National Lutheran Communities & Services (NLCS) Certified as a Great Place to Work®
- Women to Watch Summit Draws Record Numbers, Celebrating and Empowering Women in STEM
- Electives, Inc. to launch Electives Membership on June 1
- What Donald Trump Doesn't Seem To Know About Women
- Hill Helicopters Adopts GL Studio for Avionics Suite Development
- Meadowlark Optics Acquires Boulder Nonlinear Systems
- Realty Connect Expands and Enlists Happy Grasshopper to Power Agent Communication
Similar on Amzeal
- ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
- Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
- IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree
- SafeBreak® Vascular Cleared for Pediatrics
- CartoVista unveils CartoVista Cloud 8.1, the latest in GIS web mapping platforms, at 2023 FCM Conference in Toronto
- Resurgence Wellness Unveils Revolutionary Anti-Aging Breakthroughs by Tech Pioneer Bryan Johnson
- Baked by Michela Announces Grand Opening of Bucks County, Pennsylvania Bakery
- Telliant Systems Names Taylor Heath, Director of Business Development
- U.S. Small Business Advocate Molly Bakewell Chamberlin Selected as Mentor for Buffalo Niagara Medical Campus Innovation Community Success Program
- Make your Business Stand Out with a Memorable and Relevant Name From Namify's Company Name Generator
GenesisCare and OncoBeta announce partnership to provide innovative treatment for non-melanoma skin cancer
Amzeal News/10525214
Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites
MUNICH & SYDNEY - Amzeal -- OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies. And GenesisCare, the largest provider of cancer care in Australia, the UK and Spain are excited to announce a partnership to provide an innovative, non-invasive, single-session treatment for non-melanoma skin cancer. OncoBeta and GenesisCare have recently completed recruitment of a phase 4 clinical trial and are now expanding access to suitable skin cancer patients.
Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.
Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."
More on Amzeal News
"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".
GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".
Always talk to your doctor about what treatment options are suitable for you.
Healthcare Professionals can contact GenesisCare or OncoBeta for more information.
About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.
GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.
More on Amzeal News
Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.
For more information visit www.genesiscare.com/au
About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.
Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."
More on Amzeal News
- Gemini IT Producer Software is Reshaping the Filmmaking Industry
- Tech Pioneer Aims to Save the Environment with New Work-From-Anywhere Eco Venture
- SEM Link wins grant to narrow gaps in health, wealth, and opportunity for Atlanta youth
- 130k+ Patients' Social Security Numbers Leaked in UHS of Delaware Data Breach
- Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".
GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".
Always talk to your doctor about what treatment options are suitable for you.
Healthcare Professionals can contact GenesisCare or OncoBeta for more information.
About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.
GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.
More on Amzeal News
- Ohio Pacing Stallion Catch The Fire Is Heading To Australia
- IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree
- Autel Robotics Wins Prestigious Red Dot Design Award 2023 for EVO Max 4T Drone
- Launch of New Industrial Capabilities and Services Website for Argo Products in St. Louis, Missouri
- Canada's leading cybersecurity enabler launches new security protection & privacy compliance tools
Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.
For more information visit www.genesiscare.com/au
About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
Find out more at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Source: OncoBeta GmbH
0 Comments
Latest on Amzeal News
- Engineers honored at international conference in New Orleans
- Veterans for Trump Spokesman Admiral Charles Kubic signs onto push that DEI be removed from DOD
- Black Dog Venture Partners Acquires 20% Stake in St. Petersburg based, Woman Owned Music Discovery Platform Giggidy
- Internet 2.0 Conference Discusses Legit Concerns Around Misinformation Scams And The Role Of AI
- We Decode DNA Kit Named One of the Top 50 Most Innovative Products of 2023 by Innovation & Tech Today
- New Jewelry Viewing Room at Biris Jewelers
- The US Senators are Getting Satellite Phones for Security, and You Should Too
- Launch of The Who's Who Guide to Asset Tokenization
- Mensa Foundation Prize Awarded to NIH Neuroscientist
- Industry Awards Program Identifies Top Hiring, Engagement, Learning Technologies
- Victor Avila is still seeking justice for the cartel execution of partner,agent Jaime Zapata,12 years later. Murder charge now dismissed by DC court
- Costner builds a Field of Dreams - Pitt builds a Field of Power
- Birmingham Businessman is set to launch Companion, a cutting-edge social engagement app this July
- Yida Gao Welcomes Brandon Stahl as the New CFO at Shima Capital
- Honoring The Women In Our Lives
- Armie Hammer to star in American Criminals Movie to shoot in Chicago Summer 2023
- Kingwills™, With The Industry Trend Guided, Landed More Than 100 Million Yuan In Series B Funding
- Revealed: How To Optimize a Website Home Page For Search Engines
- TeroTAM announcing the success story of Property Management Solution at Airtel
- Reputation Riser Launches: CEO Tim Sumer's Solution to the Pressing Problem of Not Getting Leads from Your Website